These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12433833)

  • 41. Integrins and the myocardium.
    Ross RS; Borg TK
    Circ Res; 2001 Jun; 88(11):1112-9. PubMed ID: 11397776
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deletion of the inducible 70-kDa heat shock protein genes in mice impairs cardiac contractile function and calcium handling associated with hypertrophy.
    Kim YK; Suarez J; Hu Y; McDonough PM; Boer C; Dix DJ; Dillmann WH
    Circulation; 2006 Jun; 113(22):2589-97. PubMed ID: 16735677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control.
    Wagner M; Mascareno E; Siddiqui MA
    Ann N Y Acad Sci; 1999 Jun; 874():1-10. PubMed ID: 10415515
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulator of G protein signaling 3 protects against cardiac hypertrophy in mice.
    Liu Y; Huang H; Zhang Y; Zhu XY; Zhang R; Guan LH; Tang Q; Jiang H; Huang C
    J Cell Biochem; 2014 May; 115(5):977-86. PubMed ID: 24375609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interplay between the E2F pathway and β-adrenergic signaling in the pathological hypertrophic response of myocardium.
    Major JL; Salih M; Tuana BS
    J Mol Cell Cardiol; 2015 Jul; 84():179-90. PubMed ID: 25944088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure.
    Rothermel BA; Berenji K; Tannous P; Kutschke W; Dey A; Nolan B; Yoo KD; Demetroulis E; Gimbel M; Cabuay B; Karimi M; Hill JA
    Physiol Genomics; 2005 Sep; 23(1):18-27. PubMed ID: 16033866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. AMPK and cardiac remodelling.
    Feng Y; Zhang Y; Xiao H
    Sci China Life Sci; 2018 Jan; 61(1):14-23. PubMed ID: 29170891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sarcolemmal α2-adrenoceptors control protective cardiomyocyte-delimited sympathoadrenal response.
    Kokoz YM; Evdokimovskii EV; Maltsev AV; Nenov MN; Nakipova OV; Averin AS; Pimenov OY; Teplov IY; Berezhnov AV; Reyes S; Alekseev AE
    J Mol Cell Cardiol; 2016 Nov; 100():9-20. PubMed ID: 27659409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy.
    Hoffmann S; Krause T; van Geel PP; Willenbrock R; Pagel I; Pinto YM; Buikema H; van Gilst WH; Lindschau C; Paul M; Inagami T; Ganten D; Urata H
    J Mol Med (Berl); 2001 Oct; 79(10):601-8. PubMed ID: 11692158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regulation of cardiac contraction.
    Ross J; Sobel BE
    Annu Rev Physiol; 1972; 34():47-90. PubMed ID: 4334850
    [No Abstract]   [Full Text] [Related]  

  • 51. Tomoregulin-1 prevents cardiac hypertrophy after pressure overload in mice by inhibiting TAK1-JNK pathways.
    Bao D; Lu D; Liu N; Dong W; Lu YD; Qin C; Zhang LF
    Dis Model Mech; 2015 Aug; 8(8):795-804. PubMed ID: 26092120
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Signaling pathway mediated by kappa-opioid receptor is impaired in cardiac hypertrophy.
    Pei JM; Wang YM; Zhu YL; Chen M; Wong TM
    Acta Pharmacol Sin; 2001 Oct; 22(10):887-95. PubMed ID: 11749770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Network integration of the adrenergic system in cardiac hypertrophy.
    Barki-Harrington L; Perrino C; Rockman HA
    Cardiovasc Res; 2004 Aug; 63(3):391-402. PubMed ID: 15276464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways.
    Yasukawa H; Hoshijima M; Gu Y; Nakamura T; Pradervand S; Hanada T; Hanakawa Y; Yoshimura A; Ross J; Chien KR
    J Clin Invest; 2001 Nov; 108(10):1459-67. PubMed ID: 11714737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases.
    Kang PM; Izumo S
    Trends Mol Med; 2003 Apr; 9(4):177-82. PubMed ID: 12727144
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Many pathways to cardiac hypertrophy.
    Steinberg SF
    J Mol Cell Cardiol; 2000 Aug; 32(8):1381-4. PubMed ID: 10900164
    [No Abstract]   [Full Text] [Related]  

  • 57. NF-kappaB activation is required for adaptive cardiac hypertrophy.
    Zelarayan L; Renger A; Noack C; Zafiriou MP; Gehrke C; van der Nagel R; Dietz R; de Windt L; Bergmann MW
    Cardiovasc Res; 2009 Dec; 84(3):416-24. PubMed ID: 19620128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Role and regulation of calcineurin-dependent signal pathway in cardiac hypertrophy of rats].
    Fu MG
    Sheng Li Ke Xue Jin Zhan; 2001 Jan; 32(1):52-4. PubMed ID: 12545778
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling.
    Zhu Y; Li T; Song J; Liu C; Hu Y; Que L; Ha T; Kelley J; Chen Q; Li C; Li Y
    Basic Res Cardiol; 2011 Sep; 106(5):787-99. PubMed ID: 21533832
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cellular mechanisms of cardiac hypertrophy.
    Glennon PE; Sugden PH; Poole-Wilson PA
    Br Heart J; 1995 Jun; 73(6):496-9. PubMed ID: 7626345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.